Date: 2011-10-26
Type of information: R&D agreement
Compound: Glucopyranosyl Lipid Adjuvant (GLA) technology
Company: Sanofi (France) Immune Design Corp (USA)
Therapeutic area: Allergic diseases - Immunological diseases
Type agreement: R&D
Action mechanism: Immune Design Corp has advanced the GLA technology into early clinical stage development. This technology can be used to promote optimal activation of human dendritic cells, has demonstrated compatibility with many antigens, and has a well-established safety profile to date.
Disease: allergy
Details: Immune Design Corp, a privately held biotechnology company developing novel vaccines and immunotherapies for infectious disease, cancer and allergy, has entered into an early-stage research collaboration with Sanofi-Aventis to investigate the use of IDC\'s Glucopyranosyl Lipid Adjuvant (GLA) technology, a toll–like receptor 4 (TLR-4) agonist, in the field of allergy.
Under the agreement, Immune Design Corp will provide access to the GLA technology, allowing Sanofi the ability to evaluate the biological and immunological properties of this TLR-4 agonist in vitro and in allergy disease models, and will be granted an option to select lead candidates for further development. The terms have not been disclosed.
Financial terms:
Latest news:
